英特集团(000411) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the period was ¥5,169,955,002.33, an increase of 8.93% year-on-year[8] - Net profit attributable to shareholders was ¥25,009,279.56, a significant increase of 37.45% year-on-year[8] - Basic earnings per share rose by 37.51% to ¥0.1206[8] - Other income increased by 267.16% year-on-year, mainly due to an increase in government subsidies related to operations during the reporting period[17] Assets and Liabilities - Total assets increased by 3.52% to ¥9,403,260,063.82 compared to the end of the previous year[8] - Net assets attributable to shareholders increased by 8.49% to ¥914,973,773.32 compared to the end of the previous year[8] - Long-term borrowings increased by 109.83% compared to the end of the previous year, attributed to loans obtained by the subsidiary Yinte Pharmaceutical[16] - Non-current liabilities increased by 286.25% compared to the end of the previous year, mainly due to an increase of 250 million yuan in medium-term notes[17] Cash Flow - Cash flow from operating activities showed a negative net amount of ¥898,594,750.42 for the year-to-date[8] - Cash flow from financing activities decreased by 64.81% year-on-year, primarily due to a reduction in cash received from borrowings and an increase in cash used for debt repayment[21] - The net increase in cash and cash equivalents decreased by 485.30 million yuan year-on-year, mainly due to a reduction in cash flow from financing activities[21] - The cash received from issuing bonds increased by 250 million yuan, attributed to the issuance of medium-term notes during the reporting period[18] - Cash paid for other financing activities increased by 834.23% year-on-year, mainly due to cash repayments of inter-company loans by subsidiaries[19] Investments and Expenses - Construction in progress increased by 519.85% compared to the end of the previous year, primarily due to increased investment in the Shaoxing (Shangyu) Pharmaceutical Industry Center[16] - Sales expenses grew by 55.57% year-on-year, primarily due to increases in transportation costs, employee compensation, leasing fees, and labor costs[17] - R&D expenses increased by 94.82% year-on-year, mainly due to higher spending on information system development[17] - Asset impairment losses rose by 93.26% year-on-year, primarily due to an increase in bad debt provisions for receivables as per the company's accounting policy[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,185[12] - The company plans to issue non-public shares to raise up to 650 million yuan, pending approval from the shareholders' meeting and the China Securities Regulatory Commission[22]